Autosomal dominant optic atrophy (ADOA) is the most frequent form of hereditary optic neuropathy. It is characterized by optic nerve pallor, central or centrocecal visual field loss, color vision deficits and progressive loss of visual acuity in the early decades of life due to the degeneration of the retinal ganglion cells[@b1]. In most cases, ADOA patients experience a slowly progressive and insidious decrease of their quality of vision, which is irreversible[@b2]. The disease prevalence is between 1:12 000 to 1:50 000 in different populations[@b3][@b4].

Since this disease has no effective treatment, accurate molecular diagnosis is a crucial step for preimplantation genetic diagnosis or prenatal screening.

To date, two genes (*OPA1* and *OPA3*) and three loci (*OPA4*, *OPA5* and *OPA8*) have been associated with autosomal dominant optic atrophy. *OPA2*, *OPA6* and *OPA7* mutations are responsible for X-linked or recessive optic atrophy[@b2]. However, *OPA1* (NM_130837) is the major gene responsible for ADOA, which was first localized on 3q28 in 1996, followed by the discovery of the *OPA1* gene sequence[@b5][@b6]. *OPA1* is widely expressed, but most abundant in the retina[@b5]. It consists of 31 exons with the last exon as non-coding exon and by alternative splicing from exons 4 to 5b, it produces eight mRNA isoforms[@b7]. *OPA1* encodes a large GTPase related to dynamins, anchored to the mitochondrial cristae inner membrane, controlling the shape of mitochondrial cristae and keeping their junctions tight during apoptosis[@b8].

OPA1 cleavage has been reported[@b9]. Under conditions of stress, it is cleaved by OMA1 (overlapping with the m-AAA protease 1 homolog) to generate shorter isoforms, which trigger mitochondrial fragmentation[@b9]. Under high oxidative phosphorylation conditions, it is cleaved by YmeL, the human orthologue of the Yme1 subunit of the yeast i-AAA complex, which stimulates mitochondrial inner membrane fusion[@b10]. OPA1 also has been reported to be involved in the maintenance of the cristae structure[@b8][@b11].

The other gene responsible for ADOA is *OPA3* (NM_001017989), which encodes a mitochondrial inner membrane protein with unknown function[@b12]. The mutation in *OPA3* displayed optic atrophy plus a syndrome consisting of early onset bilateral optic atrophy, later onset spasticity, extrapyramidal signs and cognitive deficit[@b12][@b13].

In the present study, a patient diagnosed with putative ADOA was recruited. We sought to identify the genetic defect and dissect the molecular consequence of the identified mutation. By capture next generation sequencing (CNGS) and Sanger sequencing, the mutation associated with ADOA in this patient was identified. To dissect the molecular consequence of the mutation, the structure of mitochondria was examined in fibroblasts from patient skin biopsy; the gene and protein expression of OPA1 was tested by quantitative (Q)-PCR and Western blotting, respectively; and the structural changes in OPA1 protein were assessed by molecular modeling.

Results
=======

Clinical data
-------------

The family in this study comprised six affected individuals from a three generation pedigree ([Fig. 1](#f1){ref-type="fig"}). The proband was a 35 year-old female (marked with a black arrow in [Fig. 1](#f1){ref-type="fig"}). The present vision of the proband is about 20/400. Fundus examination indicated the optic disk in both eyes was well-defined and presented with a bilateral and symmetrical pallor ([Fig. 2 A, B, C](#f2){ref-type="fig"}). 3-D optical coherence tomography (OCT) scans of the optic nerve head revealed the thickness of retinal nerve fiber layer (RNFL) above and below the optic disk and partial temporal sides was obviously attenuated in both eyes ([Fig. 2 D, E](#f2){ref-type="fig"}). OCT scans showed that the macular central fovea had no obvious abnormality in either eye, but RNFL at the (rostral) nasal side and (macular) parafovea region had a tendency to be thinner ([Fig. 2 F,G](#f2){ref-type="fig"}). Flash visual evoked potential (F-VEP) showed P2 wave latencies in both eyes were normal, but amplitude was decreased, indicating defective conduction of the optic nerves ([Fig. 2H](#f2){ref-type="fig"}).

Taken together, based on the clinical manifestations and pedigree, the diagnosis of the patient from this family is putative ADOA.

Identification of the disease-causing gene
------------------------------------------

To identify the ADOA-causing gene in this family, we performed capture next generation sequencing (CNGS) to screen a panel of genes previously reported to be retinal disease genes ([Fig. 3A](#f3){ref-type="fig"}, [Table S1,S4](#s1){ref-type="supplementary-material"}), including the two known genes (*OPA1* and *OPA3*) linked with ADOA. However, we did not detect any disease-causing gene mutations but identified 6 SNPs ([Table S2](#s1){ref-type="supplementary-material"}), which includes two novel DNA variants.

We rationalize that the mutation may be located in the region of missing coverage or beyond of the panel of the captured genes ([Table S1](#s1){ref-type="supplementary-material"}). To rule out the first possibility, we retrieved the data from the CNGS and observed there was no missing coverage in *OPA3* but missing coverage of six exons and a low depth (\<5) of coverage of ten exons in *OPA1*(NM_130837). It indicates that no reliable data of more than half of the coding exons (16 of 30) has been obtained from CNGS. To fill in the missing or verify these data, we designed specific primers ([Table S3](#s1){ref-type="supplementary-material"}) to amplify these fragments and then sequenced with Sanger sequencing. The mutation analysis led to identification of 4-bp deletion mutation (gAGA, g is part of intron, AGA is part of exon 30, c.2983-1_2985del) in *OPA1* ([Fig. 3B](#f3){ref-type="fig"}). We searched for mutations identified to date in the literature and found this mutation has been previously reported in the Italian population[@b14], although the same mutation was named as c.2819-1_2821del due to using another isoform for the mutation annotation. The identification of the same variant in the affected members of the Italian and Chinese pedigrees provides support for its pathogenic nature, since it arose independently in different genetic and ethnic backgrounds.

We also scanned c.2983-1_2985del in two public DNA databases (1000 Genomes Project and ESP6500 Genomes Project) and one in-house exome database containing 1402 samples, but c.2983-1_2985del was absent in all of three DNA databases.

Skin fibroblasts from the ADOA subject have abnormal mitochondrion morphology
-----------------------------------------------------------------------------

Although clinical examination indicated degeneration of the retinal ganglion cells of the ADOA patient, it is difficult to directly study patient-specific ganglion cells *in vitro* or *in vivo*. As skin fibroblasts are readily accessible by biopsy, we selected this cell type for further study. The mitochondria of the skin fibroblasts were labeled by mitotracker and then their morphology was observed using confocal microscopy.

As shown in [Fig. 4A--D](#f4){ref-type="fig"}, the morphology of mitochondria in patient-derived fibroblasts and control is dramatically different. Specially, control fibroblasts have spotty distribution of mitochondria (here we define "spotty" as length of mitochondria \< 6.9 μm, [Fig. 4A, C](#f4){ref-type="fig"}), however, patient-derived fibroblasts have tubular distribution of mitochondria ("tubular" as length \> 6.9 μm, [Fig. 4B, D](#f4){ref-type="fig"}). Statistically, compared with spotty mitochondria in control, only 4.8% ± 2.5% of them from the patient are spotty and the rest (95.2% ± 2.5%) are tubular ([Fig. 4A--E](#f4){ref-type="fig"}). Furthermore, the mitochondrial lengths in the fibroblasts of patient were much larger than that of control (patient, 28.4 ± 5.8 μm versus control, 6.9 ± 1.4 μm, [Fig. 4A--D,F](#f4){ref-type="fig"}). As *OPA1* contributes to mitochondrial structure and biogenesis, it would not be surprising if a mutation in this gene alters mitochondrion morphology, and therefore contribute to the pathogenesis of ADOA. Interestingly, the growth rate of the patient fibroblasts was much slower than that of control (data not shown), but no obvious skin disorder was observed in this patient.

Effect of the mutation on *OPA1* transcription, protein expression and protein three-dimensional structure
----------------------------------------------------------------------------------------------------------

To assess the specific consequence of the c.2983-1_2985del mutation, we extracted mRNA from the patient skin fibroblasts, and amplified *OPA1* from the cDNA derived from these cells. These amplified fragments were inserted into a cloning vector followed by sequencing the individual clones carrying the amplified fragments. The sequencing results showed the mutant allele was transcribed and the six nucleotide deletion (c.2984-c.2989, AGAAAG) was present ([Fig. 5A](#f5){ref-type="fig"}), which produced a two lysine residue deletion (995--996 deletion) and a missense mutation (Val997Ile) ([Fig. 5B](#f5){ref-type="fig"}). This showed that the genetic deletion mutation in *OPA1* creates a new splicing acceptor ([Fig. S1](#s1){ref-type="supplementary-material"}). Since both the wild-type and mutant alleles appear to be transcribed, we counted the numbers of wild type and mutant clones we obtained, and found no significant difference in their numbers (30 clones of wild type versus 22 mutant) ([Fig. 5C](#f5){ref-type="fig"}). This indicates that there is no significant difference at steady-state transcript levels of *OPA1* between the wild type and mutant allele. We then compared the level of *OPA1* mRNA expression in the patient skin fibroblasts and control. A slight decrease but no significant of *OPA1* mRNA expression was observed in patient skin fibroblasts ([Fig. 5D](#f5){ref-type="fig"}). Western blotting analysis of protein expression extracted from the patient and control fibroblasts showed the same level of OPA1 protein expression ([Fig. 5E. F](#f5){ref-type="fig"}). Furthermore, several different isoforms of OPA1 (approximately 73 KDa, 55 KDa and 37 KDa) were detected.

To dissect the molecular mechanism at the level of protein structure, we firstly mapped the mutant residue to the OPA1 protein and found it was located at the C-terminus ([Fig. 6A](#f6){ref-type="fig"}). Multiple sequence alignments were performed and we found that codons 995--997, where the mutation occurred, were located within an extremely conserved region in various species ([Fig. 6B](#f6){ref-type="fig"}).

We predicted the secondary structure of human wild-type and mutant OPA1 using I-TASSER online software. In secondary structure prediction, the C-terminal part of the OPA1 protein (991--1010) forms an alpha helix ([Fig. 6B](#f6){ref-type="fig"}). The 3D model generated by I-TASSER suggests that this alpha helix protrudes into a pocket ([Fig. 6C](#f6){ref-type="fig"}), which will potentially affect the structure of the full protein with functional consequences.

Discussion
==========

Optic atrophy is a group of highly heterogeneous inherited diseases[@b15]. Clinical variability, both within and among families with the same disease, often makes recognition and classification difficult. Traditionally, classification has relied on the recognition of similar characteristics and similar patterns of transmission, but genetic analysis now permits the diagnosis of this disease in the absence of family history or in the setting of unusual clinical presentations[@b16]. Thus, we initially performed CNGS to identify the genetic defects in this family, but failed to discover any mutation in retinal disease gene. According to the previous study, some captured region may be missing in these tested genes[@b17]. Thus, to identify the causative mutation for the disease, filling the missing data may be necessary. Here we showed a case of filling missing CNGS data to search the causative mutation for ADOA, which raises more concern for the clinical application of the next generation sequencing.

In most cases, ADOA presents as a non-syndromic, solely bilateral optic neuropathy, but some patients have associated extra-ocular features including sensory-neural hearing loss, myopathy and peripheral neuropathy[@b18][@b19][@b20]. At least five mutations in *OPA1*, p.Arg445His, p.Gly401Asp and p.Leu243\*, p.Arg437Glu and p.Ala357Leufs\*4 have been reported in patients affected with both optic atrophy and hearing loss[@b21][@b22][@b23]. However, the proband bearing the same mutation (c.2983-1_2985del) as identified in the present study in Italian family presented optic atrophy plus phenotype, including the mild bilateral temporal pallor of the optic disc, a thinning of the peripapillar bundle nervous layers in both superior and inferior temporal quadrant bilaterally. The Italian patient also displayed a mild bilateral ptosis, ophthalmoparesis, pes cavus, the left side with a decreased/absent Achilles tendon reflex bilaterally. In our study, the patient only had a progressive decrease of vision with no other symptoms, which indicates the same *OPA1* mutation may manifest itself differently and be patient dependent and confirms the heterogeneity of this disease. However, further studies are needed to provide insights into the detailed molecular pathogenesis of the retinal ganglion cells affected by this mutation.

The mutation reported in this study occurs at an intron/exon boundary and we would predict it to affect splicing. One possible splice form (S1, [Fig. S1--2](#s1){ref-type="supplementary-material"}) is a result of the destruction of the canonical splice acceptor and creating a new splice acceptor insert site. The second possible splice form (S2, [Fig. S2](#s1){ref-type="supplementary-material"}) results from skipping exon 30, in other words, a new transcript with a splicing of exon 29 with exon 31 will be generated ([Fig. S2](#s1){ref-type="supplementary-material"}). Sequencing of *OPA1* cDNA obtained from skin fibroblasts showed that a new splice acceptor site is created resulting in the deletion of two lysine residues and a missense mutation ([Fig. S1--2](#s1){ref-type="supplementary-material"}). The same splicing form has been detected in skeletal muscle of the Italian patient[@b14], which reveals the present mutation does change the splicing both in ectoderm and mesoderm derived tissues.

Furthermore, the mutation does not affect the mRNA stability or protein expression. So far, two theories address the cause of ADOA: haploinsufficiency and dominant negative effects[@b24][@b25][@b26][@b27]. A dominant negative effect is likely to be the case in this family because both the wild-type and mutant allele appear to have similar levels of steady-state transcription, the patient and control fibroblasts have the same level of OPA1 protein expression.

In summary, this study identified a recurrent mutation in *OPA1* in an ADOA family. Our study demonstrates a case of filling missing data of CNGS to search the causative mutation for ADOA, which raises more concern for the clinical application of the next generation sequencing. We also showed the potential molecular consequence of the mutation by protein structural modeling and provided more evidence to support a dominant negative effect to explain the disease pathogenesis. Further detailed functional studies are needed to provide further insights to this inherited disease.

Methods
=======

Patient Recruitment
-------------------

This study conformed to the tenets of the Declaration of Helsinki. It was approved by the Ethics Committee of Eye Hospital, Wenzhou Medical University. Written informed consent was obtained from the recruited individuals. All experiments were performed in accordance with the approved guidelines. Optical coherence tomography (OCT), flash visual evoked potential (F-VEP) and fundus examination were performed as routine retinal ophthalmic examination. A five ml venous blood sample was drawn into an ethylenediamine tetraacetic acid (EDTA) sample tube. Genomic DNA was extracted from peripheral blood leukocytes using the standard phenol/chloroform extraction protocols. The patient skin fibroblasts and control skin fibroblasts were obtained from skin biopsies.[](#t1){ref-type="table"}

Capture Next Generation Sequencing and Bioinformatics Analysis
--------------------------------------------------------------

Capture Next Generation Sequencing was performed as previously described[@b17]. The enriched libraries were sequenced on an Illumina Solexa HiSeq 2000 sequencer for paired-end reads of 100 bp. Briefly, using the Solexa QA the cutadapt (<http://code.google.com/p/cutadapt/>), SOAP aligner, BWA and GATK programs to retrieve and align to identify SNPs and insertions or deletions (InDels). SNPs and InDels were annotated using the exome-assistant program (<http://122.228.158.106/exomeassistant>). Nonsynonymous variants were evaluated by three algorithms, SIFT (<http://sift.jcvi.org/>), PolyPhen (<http://genetics.bwh.harvard.edu/pph2/>) and PANTHER (<http://www.pantherdb.org/tools/csnpScoreForm.jsp>), to determine pathogenicity. Multiple sequence alignments were performed using ESPript3.0 (<http://espript.ibcp.fr/ESPript/cgi-bin/ESPript.cgi>).

Cell culture, mitchondria labeling and cDNA synthesis
-----------------------------------------------------

The patient skin fibroblasts and control skin fibroblasts were grown in high glucose DMEM with 10% fetal calf serum at 37°C and 5% CO~2~. The fibroblasts were seeded on coverslips inside a Petri dish filled with medium on day 2, then changed into medium containing 200 nM MitoTrackerR probe (Invitrogen, cat No.M7512) on day 3, and incubated for a further 30 minutes. Cells were then stained with DAPI, and observed using a laser Confocal microscope (Zeiss LSM710). The mitochondrial lengths in the fibroblasts were measured using Image J[@b28].

Total RNA were isolated from patient skin fibroblasts and control with TRIzol Reagent (Invitrogen, cat No.15596-026) following the manufacturer\'s instructions. cDNA synthesis was carried out with M-MLV reverse transcriptase (Invitrogen, cat No. 28025-013). The forward primer 5′-AAGGTGTCAGACAAAGAGAAAATTGAC-3′ and the reverse primer 5′ -TTATTTCTCCTGATGAAGAGCTTCAATG-3′ were used to amplify the coding sequence of *OPA1* gene, which harbors the mutation sequence, from the patient fibroblasts, then the PCR fragments were cloned into pJET vector (Fermentas cat No.K1231)and individual clones were picked and then Sanger sequenced.

Quantitative PCR
----------------

PCR primers were designed with online software (<http://www.idtdna.com/primerquest/Home/Index>). For the endogenous control, primers were designed specific to *ACTB* mRNA (NM28424.1). Sequences of primers used in this study are shown in [Table S3](#s1){ref-type="supplementary-material"}. For quantitative PCR, the cycling conditions were 95°C for 10 min, followed by 40 cycles of 95°C for 10 s and 60°C for 60 s. qPCR data was captured and analyzed using StepOne software (ver. 2.0). qPCR performed using SYBR® *Premix Ex Taq*™ II (TaKaRa, cat NO RR820A). The *OPA*1 relative mRNA expression level in the normal and patient fibroblasts were obtained by normalization to *ACTB* using the formula 2ˆ-(CT~gene~ minus CT~control~). All qPCR data was performed in triplicate.

Western blotting
----------------

For Western blotting, total proteins were extracted from the patient and control skin fibroblasts using RIPA buffer, then fractionated in a 10% SDS-PAGE gel and transferred to PVDF membranes. OPA1 was detected using a mouse anti-OPA1 monoclonal antibody (Santa Cruz, cat No.SC323936) followed by anti-mouse IgG, coupled to IRDye 800CW (Licor Biosciences, cat No. 926-32210). GAPDH was detected using a rabbit anti-GAPDH monoclonal antibody (Bioworld, cat No. AP0063), followed by anti-rabbit IgG, coupled to IRDye 680 (Licor Biosciences, cat No. 926-68071). Western blotting data was analyzed using Image J software[@b28].
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![Autosomal dominant optic atrophy (ADOA) pedigree.\
Squares and circles symbolize males and females, respectively. Black squares or circles denote affected status, but white squares or circles denote unaffected status. The arrow beside the circles represents the proband.](srep06936-f1){#f1}

![Clinical data for the left eye.\
(A) Optical coherence tomography (OCT) of the optic disc. Significant thickness map of retinal nerve fiber layer (RNFL) indicated in A (thinning parts are showed in red). (B) Eye fundus photos for optic disc. (C), Eye fundus photos. (D--E) The pie chart of RNFL thickness in the left eye. Red parts indicate the significant RNFL thinning. (F) 3D scan section figure of the macular. (G), RNFL thickness map of the macular. RNFL thickness of central fovea is normal, while parafovea and nasal perifovea are significantly thinner. (K) Flash visual evoked potential (F-VEP). N1, N2, P1, P2 indicate the different waves and decreased P2 peak indicates the blocking of optic nerve.](srep06936-f2){#f2}

![Identification of *OPA1* mutation.\
Mean coverage of Capture Next Generation Sequencing. (A) Mean coverage of 80× over the targeted region was achieved; A portion of the sequenced region is shown. Additional Capture Next Generation Sequencing information is in [Table S1, S4](#s1){ref-type="supplementary-material"}. (B) Sequencing results of *OPA1* mutation in the patient DNA. This revealed that the patient has a heterozygous mutation. Cloning of the PCR products carrying the mutation and resequenced, confirmed that the mutant allele has 4-base pair deletion.](srep06936-f3){#f3}

![Mitochondria morphology in skin fibroblasts.\
The mitochondrion was labeled using the MitoTracker probe. MitoTracker (red) staining shows aberrant mitochondrial morphology and distribution in fibroblasts with the mutation. (A) Normal fibroblasts (Control) have spotty distribution of mitochondria. (B) Patient-derived fibroblasts have tubular distribution of mitochondria. Nuclei are labeled with DAPI. Scale bars = 20 μm in A, B. (C--D) The higher magnification view of A and B. (E) The different mitochondrial distribution in control and fibroblast of patient, respectively. (F) The average length of mitochondria in fibroblasts from the patient and control. HF-M represents the patient skin fibroblasts (HF-M, [h]{.ul}uman skin [f]{.ul}ibroblasts with [m]{.ul}utation).](srep06936-f4){#f4}

![*OPA*1 mRNA and protein expression in patient skin fibroblasts.\
(A) Sequencing of clones from *OPA*1 cDNA PCR products. (B) *OPA*1 mutation analysis. A two residue deletion (995Lys-996Lys) and a missense mutation (Val997Ile) were observed. (C) Relative *OPA*1 mRNA expression levels in patient skin fibroblasts (HF-M, [h]{.ul}uman skin [f]{.ul}ibroblasts with [m]{.ul}utation) and control. (D) The transcription of the wild type and mutant allele in patient skin fibroblasts. RT-PCR products, harbors the mutation sequence, were cloned into pJET vector; individual clones were picked and then Sanger sequenced. (E) Western blotting for OPA1. (F) The quantitative analysis of Western blotting result was performed using Image J software.](srep06936-f5){#f5}

![Mutant OPA1 protein analysis.\
(A) Multiple-sequence alignment of OPA1 from different species. The red square indicates the location of the deletion and missense mutation we identified in OPA1 (B) Alpha helical structure of OPA1. The upper sequence is the control; the lower is the OPA1 with deletion/missense mutation. The arrow indicates the location of the deletion/missense mutation in OPA1. The region containing the deletion/missense mutation is predicted to form an alpha helical structure, which was absent from the wild type. (C)In secondary structure predication, the C-ter part (991--1010) forms an alpha helix. The model generated by I-TASSER suggests that this conserved helix (shown in orange), where the mutation is located, protrudes into a pocket. Interruption between this helix and the rest of the pocket will potentially affect the structural intact of the protein.](srep06936-f6){#f6}

###### CNGS of *OPA1* and *OPA3* genes

  Gene           Exon         Physical location         Length    Sequencing Depth
  ------------ -------- ------------------------------ --------- ------------------
  *OPA1*          1        chr3:193311117-193311247       130            60
  *OPA1*          2        chr3:193332511-193332830       319            18
  *OPA1*          3        chr3:193333446-193333575       129            10
  *OPA1*          4        chr3:193334955-193335085       130            3
  *OPA1*          5        chr3:193335534-193335664       130            10
  *OPA1*          6        chr3:193336626-193336756       130            13
  *OPA1*          7        chr3:193343871-193344000       129            18
  *OPA1*          8        chr3:193349362-193349492       130            2
  *OPA1*          9        chr3:193353194-193353323       129            0
  *OPA1*          10       chr3:193354962-193355091       129            0
  *OPA1*          11       chr3:193355732-193355862       130            36
  *OPA1*          12       chr3:193360529-193360658       129            2
  *OPA1*          13       chr3:193360736-193360865       129            4
  *OPA1*          14       chr3:193361132-193361262       130            2
  *OPA1*          15       chr3:193361301-193361431       130            2
  *OPA1*          16       chr3:193361763-193361894       131            9
  *OPA1*          17       chr3:193363313-193363442       129            2
  *OPA1*          18       chr3:193363488-193363617       129            2
  *OPA1*          19       chr3:193364846-193364976       130            4
  *OPA1*          20       chr3:193365826-193365955       129            3
  *OPA1*          21       chr3:193366557-193366686       129            0
  *OPA1*          22       chr3:193372650-193372816       166            8
  *OPA1*          23       chr3:193374868-193375021       153            0
  *OPA1*          24       chr3:193376665-193376794       129            9
  *OPA1*          25       chr3:193377245-193377375       130            5
  *OPA1*          26       chr3:193380610-193380751       141            20
  OPA1            27       chr3:193382662-193382791       129            0
  *OPA1*          28       chr3:193384066-193384196       130            20
  *OPA1*          29       chr3:193384949-193385078       129            6
  ***OPA1***    **30**   **chr3:193409819-193409948**   **129**        **0**
  *OPA3*          1        chr19:46056771-46057169        398           220
  *OPA3*          2        chr19:46087880-46088022        142           109

[^1]: These authors contributed equally to this work.
